Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Berg LLC has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners and 5 distinct art units, indicating separate examiner and technical assignments throughout the profile.
HALVORSON, MARK is the busiest examiner, with 1 pending matter. Because the matters are distributed across examiners and art units, counsel should use matter-specific response strategies while maintaining portfolio-level consistency where claim themes overlap.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §112 only | 2 (40%) |
| Double-patenting + other | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HALVORSON, MARK | 1 | 47.9% | +20.7% |
| SOROUSH, LAYLA | 1 | 40.4% | +43.6% |
| PLAYER, ROBERT AUSTIN | 1 | 12.5% | +34.7% |
| RODRIGUEZ, RAYNA B | 1 | 33.5% | +19.2% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 56.4% | +39.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17953075 | SYSTEMS AND METHODS FOR PATIENT STRATIFICATION AND IDENTIFICATION OF POTENTIAL BIOMARKERS | PLAYER, ROBERT AUSTIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17274405 | METHODS OF TREATING CANCER BY INHIBITING UBIQUITIN CONJUGATING ENZYME E2 K (UBE2K) | SULLIVAN, STEPHANIE LAUREN | 71d overdue |
| 17981038 | PREVENTING OR MITIGATING CHEMOTHERAPY INDUCED ALOPECIA USING VITAMIN D | SOROUSH, LAYLA | 44d overdue |
| 18653809 | USE OF MARKERS INCLUDING FILAMIN A IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | HALVORSON, MARK | — |
| 17953075 | SYSTEMS AND METHODS FOR PATIENT STRATIFICATION AND IDENTIFICATION OF POTENTIAL BIOMARKERS | PLAYER, ROBERT AUSTIN | — |
| 17341027 | PREVENTING OR MITIGATING CHEMOTHERAPY INDUCED ALOPECIA USING VITAMIN D | RODRIGUEZ, RAYNA B | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1622 | 1 |
| 1672 | 1 |
| 1628 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18653809 | USE OF MARKERS INCLUDING FILAMIN A IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | HALVORSON, MARK | 1646 | §112Other | Non-Final OA | — | Pending | May 02, 2024 |
| 17981038 | PREVENTING OR MITIGATING CHEMOTHERAPY INDUCED ALOPECIA USING VITAMIN D | SOROUSH, LAYLA | 1622 | §103DP | Final Rejection | 44d overdue | Pending | Nov 04, 2022 |
| 17953075 | SYSTEMS AND METHODS FOR PATIENT STRATIFICATION AND IDENTIFICATION OF POTENTIAL BIOMARKERS | PLAYER, ROBERT AUSTIN | 1672 | §101§103§112DP | Non-Final OA | — | Pending | Sep 26, 2022 |
| 17341027 | PREVENTING OR MITIGATING CHEMOTHERAPY INDUCED ALOPECIA USING VITAMIN D | RODRIGUEZ, RAYNA B | 1628 | §103DP | Non-Final OA | — | Pending | Jun 07, 2021 |
| 17274405 | METHODS OF TREATING CANCER BY INHIBITING UBIQUITIN CONJUGATING ENZYME E2 K (UBE2K) | SULLIVAN, STEPHANIE LAUREN | 1635 | §112 | Final Rejection | 71d overdue | Pending | Mar 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBerg LLC has 5 pending office actions as of November 2026, spread across 5 art units and 5 examiners.
Mark Halvorson has the most, with 1 of Berg LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.